# Pieter van der Meer

> Pieter van der Meer is a Series D investor at Gilde Healthcare backing Biotechnology and Medical. See 10 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Gilde Healthcare](https://shizune.co/investors/profile/gilde-healthcare-partners)
- Location: The Hague, The Netherlands
- Total investments: 10
- Last investment: Apr 2021
- Lead investor: 20%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/pieter-van-der-meer-762318

Pieter van der Meer is a Series D investor at Gilde Healthcare in The Hague focused on Biotechnology and Medical. Pieter van der Meer joined Gilde in 1998 following a consultant position with KPMG Management Consulting in the Netherlands. At KPMG, Pieter was involved with due diligence and strategic projects within various sectors. Pieter van der Meer was a member of the Working Group of the Dutch Participation Association (NVP), advising the Ministry ofEconomic Affairs on policy to stimulate early stage venture creation. He is a member of the project screening committees at Dutch Universities. He holds a master degree in Chemistry from Leiden University, specializing in bio-organic synthesis and molecular modeling. Pieter van der Meer is a Dutch national and speaks English and Spanish. He led investments in Ablynx, Acacia Pharma, Agendia, Inpharmatica and BG Medicine. He represented Gilde on the board of Ablynx and is currently on the boards of Acacia Pharma, Agendia and BG Medicine.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 5 | 50% |
| Medical | 3 | 30% |
| Genetics | 2 | 20% |
| Health Care | 2 | 20% |
| Life Science | 2 | 20% |

13 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series D | 3 | 30% |
| Series A | 2 | 20% |
| Series B | 2 | 20% |
| Series C | 1 | 10% |
| Series E | 1 | 10% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| The Netherlands | 3 | 30% |
| United States | 1 | 10% |
| United Kingdom | 1 | 10% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| LUMICKS | LUMICKS delivers state-of-the-art technologies for the study of biology and cancer at the single-molecule and single-cell levels. It aims to build the unfinished bridge between structure and function at the molecular and cellular levels. Using its product C-Trap Optical Tweezers, Fluorescence Microscopy, scientists are able to analyze complexbiological processes in real-time. Similarly, the z-Movi Cell Avidity Analyzer enables the measurement and selection of immune cells based on their real-time interactions with target cells. | $93M | Series D | Apr 16, 2021 |  |
| LUMICKS | LUMICKS delivers state-of-the-art technologies for the study of biology and cancer at the single-molecule and single-cell levels. It aims to build the unfinished bridge between structure and function at the molecular and cellular levels. Using its product C-Trap Optical Tweezers, Fluorescence Microscopy, scientists are able to analyze complexbiological processes in real-time. Similarly, the z-Movi Cell Avidity Analyzer enables the measurement and selection of immune cells based on their real-time interactions with target cells. |  | Series A | Jan 01, 2017 |  |
| Nightbalance | NightBalance B.V. is an enterprise which was started by TU Delft alumni. In 2007 the research into improved position therapy aids began at the Delft University of Technology. NightBalance was founded in 2009 based on the research at the university in order to further develop the Sleep Position Trainer. |  | Series B | Jul 05, 2016 |  |
| Acacia Pharma | Acacia Pharma Ltd., a pharmaceutical company, discovers and develops supportive care drugs. The company focuses on cancer supportive care. Its products include APD405, an injectable formulation of an oral drug for the use of nausea and vomiting; APD209, which is for the use of cancer cachexia; and APD421, an intravenous formulation for the use ofprevention and treatment of nausea and vomiting. The company also concentrates its discovery efforts in cancer related fatigue, cancer cachexia, and xerostomia. Acacia Pharma Ltd. was incorporated in 2006 and is based in Cambridge, United Kingdom. |  | Series B | Sep 03, 2013 |  |
| Agendia | Agendia's molecular diagnostic technology provides cancer patients and their physicians with a glimpse into their genome, answers to the most pressing questions and enables personalized treatment plans. Agendia’s breast cancer tests were developed using an unbiased gene selection by analyzing the complete human genome. Agendia’s tests canhelp physicians assess a patient’s individual risk for metastasis, which patients may benefit from chemo, hormonal or combination therapy, and which patients may not require these treatments and can instead be treated with other, less arduous and less costly methods. | $65M | Private Equity | May 31, 2012 |  |
| Acacia Pharma | Acacia Pharma Ltd., a pharmaceutical company, discovers and develops supportive care drugs. The company focuses on cancer supportive care. Its products include APD405, an injectable formulation of an oral drug for the use of nausea and vomiting; APD209, which is for the use of cancer cachexia; and APD421, an intravenous formulation for the use ofprevention and treatment of nausea and vomiting. The company also concentrates its discovery efforts in cancer related fatigue, cancer cachexia, and xerostomia. Acacia Pharma Ltd. was incorporated in 2006 and is based in Cambridge, United Kingdom. | $10M | Series A | Mar 31, 2011 |  |
| Agendia | Agendia's molecular diagnostic technology provides cancer patients and their physicians with a glimpse into their genome, answers to the most pressing questions and enables personalized treatment plans. Agendia’s breast cancer tests were developed using an unbiased gene selection by analyzing the complete human genome. Agendia’s tests canhelp physicians assess a patient’s individual risk for metastasis, which patients may benefit from chemo, hormonal or combination therapy, and which patients may not require these treatments and can instead be treated with other, less arduous and less costly methods. |  | Series E | Sep 23, 2009 |  |
| BG Medicine | BG Medicine is a life sciences company focused on the discovery, development, and commercialization of novel diagnostic tests based on biomarkers for high-value market opportunities in healthcare that they identify. | $40M | Series D | Jul 17, 2008 |  |
| Agendia | Agendia's molecular diagnostic technology provides cancer patients and their physicians with a glimpse into their genome, answers to the most pressing questions and enables personalized treatment plans. Agendia’s breast cancer tests were developed using an unbiased gene selection by analyzing the complete human genome. Agendia’s tests canhelp physicians assess a patient’s individual risk for metastasis, which patients may benefit from chemo, hormonal or combination therapy, and which patients may not require these treatments and can instead be treated with other, less arduous and less costly methods. |  | Series D | Aug 28, 2007 |  |
| Agendia | Agendia's molecular diagnostic technology provides cancer patients and their physicians with a glimpse into their genome, answers to the most pressing questions and enables personalized treatment plans. Agendia’s breast cancer tests were developed using an unbiased gene selection by analyzing the complete human genome. Agendia’s tests canhelp physicians assess a patient’s individual risk for metastasis, which patients may benefit from chemo, hormonal or combination therapy, and which patients may not require these treatments and can instead be treated with other, less arduous and less costly methods. |  | Series C | Jun 07, 2006 |  |

10 of 10 investments shown.

## Co-investors
- [Global Life Science Ventures](https://shizune.co/investors/profile/global-life-science-ventures) — VC Fund, 2 deals together
- [Lundbeckfonden Ventures](https://shizune.co/investors/profile/lundbeckfond-ventures) — VC Fund, 2 deals together
- [Eight Roads Ventures](https://shizune.co/investors/profile/eight-roads-ventures) — VC Fund, 1 deal together
- [Farallon Capital Management](https://shizune.co/investors/profile/farallon-capital-management) — VC Fund, 1 deal together
- [F-Prime](https://shizune.co/investors/profile/f-prime-capital-partners) — VC Fund, 1 deal together
- [Health Innovation Fund](https://shizune.co/investors/profile/health-innovation-fund) — VC Fund, 1 deal together

## About Gilde Healthcare

VC Fund · Utrecht, The Netherlands

Gilde Healthcare is a specialized European healthcare investor managing two business lines: a lower mid-market buy-out fund and a venture & growth capital fund. It has over €800 million ($900 million) under management and is actively looking to lead new investments in digital health, diagnostics, medical devices, therapeutics and healthcareservices. Gilde successfully builds healthcare businesses across Europe and US, investing up to €35 million in a single portfolio company.

5 contacts available at Gilde Healthcare.

| Name | Title | Profile |
| --- | --- | --- |
| Edwin Graaf | Managing Partner | https://shizune.co/investors/profile/edwin-de-graaf |
| Joep Muijrers | General Partner | https://shizune.co/investors/profile/joep-muijrers |
| Pieter van der Meer | Managing Partner & Founder | https://shizune.co/investors/profile/pieter-van-der-meer |
| Stefan Luzi | Partner | https://shizune.co/investors/profile/stefan-luzi |
| Arthur Franken | Partner | https://shizune.co/investors/profile/arthur-franken |

## Similar investors

### Similar stage
- [Sigma Partners](https://shizune.co/investors/profile/sigma-partners) — VC Fund
- [EDBI](https://shizune.co/investors/profile/edbi) — VC Fund
- [Trifecta Capital Advisors](https://shizune.co/investors/profile/trifecta-capital-advisors) — VC Fund

## FAQ

### What does Pieter van der Meer invest in?

Pieter van der Meer invests primarily in Biotechnology, Medical and Genetics startups, most often at Series D and Series A stage. Most of the 10 investments tracked by Shizune back companies in The Netherlands. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Pieter van der Meer last invest?

The most recent investment recorded for Pieter van der Meer closed in Apr 2021. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co